Michael Wortley - Reata Pharmaceuticals Vice President Chief Legal Officer
President
Mr. Michael D. Wortley is the Executive Vice President, Chief Legal Officer of Reata Pharmaceuticals Inc. Prior to joining Reata, Prior to joining Reata, Mr. Wortley was an attorney at Vinson Elkins LLP from 1995 to March 2015, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and, prior to 1995, at Johnson Wortley, P.C., serving as Chairman of the Board and President. He currently serves on the board of directors of Pioneer Natural Resources Company since 2018.
| Age | 75 |
| Tenure | 7 years |
| Phone | 972 865 2219 |
| Web | https://www.reatapharma.com |
Michael Wortley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Wortley against Reata Pharmaceuticals stock is an integral part of due diligence when investing in Reata Pharmaceuticals. Michael Wortley insider activity provides valuable insight into whether Reata Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Reata Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Reata Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Wortley over a year ago Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 4125 shares of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals |
Reata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reata Pharmaceuticals currently holds 119.46 M in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Reata Pharmaceuticals has a current ratio of 10.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reata Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 3 records | PRESIDENT Age | ||
| Erin MD | Terns Pharmaceuticals | 53 | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Suma Krishnan | Krystal Biotech | 60 | |
Management Performance
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 |
Reata Pharmaceuticals Leadership Team
Elected by the shareholders, the Reata Pharmaceuticals' board of directors comprises two types of representatives: Reata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reata. The board's role is to monitor Reata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren Huff, Chairman of the Board and Presidentident, CEO | ||
| Christian Wigley, VP Officer | ||
| Bhaskar Anand, VP Officer | ||
| Michael Wortley, Vice President Chief Legal Officer | ||
| Dawn Bir, Chief Commercial Officer | ||
| Colin MD, Ex Officer | ||
| Manmeet Soni, CFO COO | ||
| Elaine Castellanos, Consultant | ||
| Steve Harman, VP Officer | ||
| Dakota Gallivan, VP Officer |
Reata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |